These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

997 related articles for article (PubMed ID: 25792263)

  • 1. Organs-on-chips at the frontiers of drug discovery.
    Esch EW; Bahinski A; Huh D
    Nat Rev Drug Discov; 2015 Apr; 14(4):248-60. PubMed ID: 25792263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screening out irrelevant cell-based models of disease.
    Horvath P; Aulner N; Bickle M; Davies AM; Nery ED; Ebner D; Montoya MC; Östling P; Pietiäinen V; Price LS; Shorte SL; Turcatti G; von Schantz C; Carragher NO
    Nat Rev Drug Discov; 2016 Nov; 15(11):751-769. PubMed ID: 27616293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Have microfluidics delivered for drug discovery?
    Chandrasekaran A; Abduljawad M; Moraes C
    Expert Opin Drug Discov; 2016 Aug; 11(8):745-8. PubMed ID: 27266956
    [No Abstract]   [Full Text] [Related]  

  • 4. Microphysiological Systems (Tissue Chips) and their Utility for Rare Disease Research.
    Low LA; Tagle DA
    Adv Exp Med Biol; 2017; 1031():405-415. PubMed ID: 29214585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Organs-on-a-chip: a new tool for drug discovery.
    Polini A; Prodanov L; Bhise NS; Manoharan V; Dokmeci MR; Khademhosseini A
    Expert Opin Drug Discov; 2014 Apr; 9(4):335-52. PubMed ID: 24620821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Big pharma screening collections: more of the same or unique libraries? The AstraZeneca-Bayer Pharma AG case.
    Kogej T; Blomberg N; Greasley PJ; Mundt S; Vainio MJ; Schamberger J; Schmidt G; Hüser J
    Drug Discov Today; 2013 Oct; 18(19-20):1014-24. PubMed ID: 23127858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Open access high throughput drug discovery in the public domain: a Mount Everest in the making.
    Roy A; McDonald PR; Sittampalam S; Chaguturu R
    Curr Pharm Biotechnol; 2010 Nov; 11(7):764-78. PubMed ID: 20809896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Organ/body-on-a-chip based on microfluidic technology for drug discovery.
    Kimura H; Sakai Y; Fujii T
    Drug Metab Pharmacokinet; 2018 Feb; 33(1):43-48. PubMed ID: 29175062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microfluidics contribution to pharmaceutical sciences: From drug discovery to post marketing product management.
    Nys G; Fillet M
    J Pharm Biomed Anal; 2018 Sep; 159():348-362. PubMed ID: 30032003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modern phenotypic drug discovery is a viable, neoclassic pharma strategy.
    Lee JA; Uhlik MT; Moxham CM; Tomandl D; Sall DJ
    J Med Chem; 2012 May; 55(10):4527-38. PubMed ID: 22409666
    [No Abstract]   [Full Text] [Related]  

  • 11. European lead factory opens for business.
    Mullard A
    Nat Rev Drug Discov; 2013 Mar; 12(3):173-5. PubMed ID: 23449292
    [No Abstract]   [Full Text] [Related]  

  • 12. Primary cells and stem cells in drug discovery: emerging tools for high-throughput screening.
    Eglen R; Reisine T
    Assay Drug Dev Technol; 2011 Apr; 9(2):108-24. PubMed ID: 21186936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biophysics in drug discovery: impact, challenges and opportunities.
    Renaud JP; Chung CW; Danielson UH; Egner U; Hennig M; Hubbard RE; Nar H
    Nat Rev Drug Discov; 2016 Oct; 15(10):679-98. PubMed ID: 27516170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel trends in high-throughput screening.
    Mayr LM; Bojanic D
    Curr Opin Pharmacol; 2009 Oct; 9(5):580-8. PubMed ID: 19775937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An industrial perspective on contemporary applications of PBPK models in drug discovery and development.
    Smith BJ
    Biopharm Drug Dispos; 2012 Mar; 33(2):53-4. PubMed ID: 22407480
    [No Abstract]   [Full Text] [Related]  

  • 16. Micro- and nanofluidic systems for high-throughput biological screening.
    Hong J; Edel JB; deMello AJ
    Drug Discov Today; 2009 Feb; 14(3-4):134-46. PubMed ID: 18983933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. De-risking drug discovery with ADDME -- avoiding drug development mistakes early.
    Tsaioun K; Jacewicz M
    Altern Lab Anim; 2009 Sep; 37 Suppl 1():47-55. PubMed ID: 19807206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-Content Assessment of Cardiac Function Using Heart-on-a-Chip Devices as Drug Screening Model.
    Conant G; Lai BFL; Lu RXZ; Korolj A; Wang EY; Radisic M
    Stem Cell Rev Rep; 2017 Jun; 13(3):335-346. PubMed ID: 28429185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The latest advances in high content screening in microfluidic devices.
    Liu W; Wang J; Qi H; Jiao Q; Wu L; Wang Y; Liang Q
    Expert Opin Drug Discov; 2023 Jul; 18(7):781-795. PubMed ID: 37219918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The development of high-content screening (HCS) technology and its importance to drug discovery.
    Fraietta I; Gasparri F
    Expert Opin Drug Discov; 2016; 11(5):501-14. PubMed ID: 26971542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.